Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C

Journal of Viral Hepatitis
C O'Brien

Abstract

Many of the major advances in treating patients for chronic hepatitis C have been made based on the results of randomized, double-blind, controlled clinical trials. However, given the large number of hepatitis C medications in development, physicians need to understand the unique elements and types of clinical trials in order to make accurate comparisons of differing drug efficacy claims. Clinicians also need to be aware of the various factors that can influence the outcomes and interpretations of these trials, irrespective of the intervention under study. For example, similar trials conducted in the United States and Europe may have different outcomes simply because the study populations differ. Thus, both trial design and patient population are important considerations in the design and analysis of clinical trials for patients with chronic hepatitis C.

References

Nov 30, 1989·The New England Journal of Medicine·G L DavisUNKNOWN Hepatitis Interventional Therapy Group
Aug 10, 1970·JAMA : the Journal of the American Medical Association·R R MillerJ Paxinos
Feb 1, 1995·JAMA : the Journal of the American Medical Association·K F SchulzD G Altman
Mar 3, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S A VillanoD L Thomas
Aug 19, 1999·The New England Journal of Medicine·M J AlterH S Margolis
Aug 19, 2000·Hematology/oncology Clinics of North America·M L Meldrum
Aug 19, 2000·Hematology/oncology Clinics of North America·S B Green
Aug 19, 2000·Hematology/oncology Clinics of North America·L V Rubinstein
Dec 7, 2000·The New England Journal of Medicine·S ZeuzemM J Brunda
Jul 7, 2001·The New England Journal of Medicine·G M Lauer, B D Walker
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Oct 3, 2002·Gastroenterology·John G McHutchisonUNKNOWN International Hepatitis Interventional Therapy Group
May 30, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jennifer E Layden-AlmerThomas J Layden
Aug 27, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Gary L DavisJanice Albrecht
Mar 5, 2004·Annals of Internal Medicine·Stephanos J HadziyannisUNKNOWN PEGASYS International Study Group
Apr 20, 2004·Critical Care Medicine·R Phillip DellingerUNKNOWN Surviving Sepsis Campaign Management Guidelines Committee
Aug 25, 2004·Gastroenterology Clinics of North America·Sangik Oh, Nezam H Afdhal
Sep 1, 2004·The American Journal of Medicine·Brian L Pearlman
Feb 11, 2005·Proceedings of the National Academy of Sciences of the United States of America·Theo HellerT Jake Liang
Mar 12, 2005·American Journal of Physical Anthropology·UNKNOWN Diverse Populations Collaborative Group
Mar 29, 2005·Antimicrobial Agents and Chemotherapy·Victoria ChungEric A D'Souza
Jul 19, 2005·Clinics in Liver Disease·Nikolaos Pyrsopoulos, Lennox Jeffers
Oct 7, 2005·Clinics in Liver Disease·Mark S Sulkowski

❮ Previous
Next ❯

Citations

Nov 8, 2012·European Journal of Public Health·Janet JunQing ChuRalf Reintjes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.